28 April 2023 - The agenda for the May 2023 PBAC intracycle meeting is now available.

The PBAC will consider six submissions:

• Carmellose with glycerin and hyaluronic acid (Optive Fusion) - initial submission was deferred in March 2023
• Darolutamide (Nubeqa) - initial submission was deferred in November 2022
• Fluticasone propionate (Axotide Junior, Flixotide Junior) - review of use in children under 6 years of age with asthma
• Hyaluronic acid with polyethylene glycol 400 and propylene glycol and hydroxypropyl guar (Systane Hydration) - initial submission was deferred in March 2023
  
• Inclisiran sodium (Leqvio) - first submission considered by the PBAC was rejected in March 2023. Interestingly, Novartis has again sought a listing for second-line use; the PBAC considered it should be used as a third-line treatment.
• Pembrolizumab (Keytruda) - submission from the Melanoma Institute Australia to include its use in the neo-adjuvant setting for patients with advanced malignant melanoma (currently listed for use in the adjuvant setting) 

Read PBAC agenda